NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
CARMEL, Ind., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
The AgeTech company experienced impressive growth over the last year with a major acquisition and increased deployment in senior living...
Recognition of Continued Growth Comes as Company Celebrates its 15th AnniversaryTOWSON, Md., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Vistant, a...
LAS VEGAS, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Dr. Jack Jacobs, Chief Science Officer of Zhittya Genesis Medicine, Inc. (a...
DENVER, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative...
TAMPA, Fla., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Nextech, a complete healthcare technology solution for specialty providers, announced today the...
Non-profit to Kick Off Back-to-School Campaign with a Times Square Billboard on National Non-Profit Day CYCLE Kids A Bike Can...
-Clinical outcomes presented at Military Health System Research Symposium (MHSRS)- -Results will be included in Biologics License Application (BLA) planned...
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a...
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE...
Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to...
Tampa, FL, Aug. 15, 2023 (GLOBE NEWSWIRE) -- DAS Health, a leading provider of health IT and management solutions, is...
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success...
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON, Aug. 15, 2023 (GLOBE...
Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected...
ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on...
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new...
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports solid underlying sales growth...
Greenville, South Carolina, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based...